Brand names: Propranolol Hydrochloride
22 interactions on record
The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol.
Source: FDA drug label - propranolol hydrochloride
Substrates or Inhibitors of CYP1A2 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. Substrates or Inhibitors of CYP1A2 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan.
Source: FDA drug label - propranolol hydrochloride
Benzodiazepines Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol. Benzodiazepines Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.
Source: FDA drug label - propranolol hydrochloride
Postural hypotension has been reported in patients taking both beta-blockers and terazosin or doxazosin.
Source: FDA drug label - propranolol hydrochloride
Substrates or Inhibitors of CYP2C19 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2C19, such as fluconazole, cimetidine, fluoxetine, fluvoxamine, teniposide, and tolbutamide. Substrates or Inhibitors of CYP2C19 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2C19, such as fluconazole, cimetidine, fluoxetine, fluvoxamine, teniposide, and tolbutamide.
Source: FDA drug label - propranolol hydrochloride
Propranolol did not have an effect on the pharmacokinetics of fluvastatin. Propranolol did not have an effect on the pharmacokinetics of fluvastatin. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.
Source: FDA drug label - propranolol hydrochloride
No interactions were observed with either ranitidine or lansoprazole. No interactions were observed with either ranitidine or lansoprazole.
Source: FDA drug label - propranolol hydrochloride
The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol.
Source: FDA drug label - propranolol hydrochloride
Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.
Source: FDA drug label - propranolol hydrochloride
Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol's pharmacokinetics. Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol's pharmacokinetics. Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol's pharmacokinetics.
Source: FDA drug label - propranolol hydrochloride
Calcium Channel Blockers The mean C max and AUC of propranolol are increased, respectively, by 50% and 30% by co‑administration of nisoldipine and by 80% and 47%, by co‑administration of nicardipine. Calcium Channel Blockers The mean C max and AUC of propranolol are increased, respectively, by 50% and 30% by co‑administration of nisoldipine and by 80% and 47%, by co‑administration of nicardipine. Calcium Channel Blockers The mean C max and AUC of propranolol are increased, respectively, by 50% and 30% by co‑administration of nisoldipine and by 80% and 47%, by co‑administration of nicardipine.
Source: FDA drug label - propranolol hydrochloride
The mean C max and AUC of nifedipine are increased by 64% and 79%, respectively, by co‑administration of propranolol. The mean C max and AUC of nifedipine are increased by 64% and 79%, respectively, by co‑administration of propranolol. The mean C max and AUC of nifedipine are increased by 64% and 79%, respectively, by co‑administration of propranolol.
Source: FDA drug label - propranolol hydrochloride
Calcium Channel Blockers The mean C max and AUC of propranolol are increased, respectively, by 50% and 30% by co‑administration of nisoldipine and by 80% and 47%, by co‑administration of nicardipine. Calcium Channel Blockers The mean C max and AUC of propranolol are increased, respectively, by 50% and 30% by co‑administration of nisoldipine and by 80% and 47%, by co‑administration of nicardipine. Calcium Channel Blockers The mean C max and AUC of propranolol are increased, respectively, by 50% and 30% by co‑administration of nisoldipine and by 80% and 47%, by co‑administration of nicardipine.
Source: FDA drug label - propranolol hydrochloride
No interaction was observed with omeprazole. No interaction was observed with omeprazole.
Source: FDA drug label - propranolol hydrochloride
The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol.
Source: FDA drug label - propranolol hydrochloride
Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.
Source: FDA drug label - propranolol hydrochloride
Alpha Blockers Prazosin has been associated with prolongation of first dose hypotension in the presence of beta-blockers.
Source: FDA drug label - propranolol hydrochloride
Drug Interactions Interactions with Substrates, Inhibitors or Inducers of Cytochrome P-450 Enzymes Because propranolol's metabolism involves multiple pathways in the cytochrome P-450 system (CYP2D6, 1A2, 2C19), co-administration with drugs that are metabolized by, or effect the activity (induction or inhibition) of one or more of these pathways may lead to clinically relevant drug interactions (see Drug Interactions under PRECAUTIONS ). Substrates or Inhibitors of CYP2D6 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. Substrates or Inhibitors of CYP1A2 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan.
Source: FDA drug label - propranolol hydrochloride
Substrates or Inhibitors of CYP2D6 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir. Substrates or Inhibitors of CYP1A2 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan. Substrates or Inhibitors of CYP2D6 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, paroxetine, quinidine, and ritonavir.
Source: FDA drug label - propranolol hydrochloride
Postural hypotension has been reported in patients taking both beta-blockers and terazosin or doxazosin.
Source: FDA drug label - propranolol hydrochloride
Substrates or Inhibitors of CYP2C19 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2C19, such as fluconazole, cimetidine, fluoxetine, fluvoxamine, teniposide, and tolbutamide. Substrates or Inhibitors of CYP2C19 Blood levels and/or toxicity of propranolol may be increased by co-administration with substrates or inhibitors of CYP2C19, such as fluconazole, cimetidine, fluoxetine, fluvoxamine, teniposide, and tolbutamide.
Source: FDA drug label - propranolol hydrochloride
The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol.
Source: FDA drug label - propranolol hydrochloride